1. 23andMe for your immune system.

• AditxtScore: A technology platform that enables individuals to understand, manage, and monitor their immune profiles.
• Apoptotic DNA Immunotherapy (ADi): A nucleic acid-based technology designed to induce immune tolerance by mimicking the body's natural processes.
• ADi product pipeline: Therapeutic products leveraging ADi technology for applications including organ transplantation, skin grafting, autoimmune diseases, and allergies.

• Individuals seeking personalized immune health insights: This category comprises individuals who utilize AditxtScore to proactively understand, manage, and monitor their immune profiles. They are interested in personalized health information for general wellness, preventative care, or early detection related to their immune system.
• Patients requiring immune modulation for organ transplantation or skin grafting: These customers include patients who are recipients of organ transplants or skin grafts. Aditxt's Apoptotic DNA Immunotherapy (ADi) products are developed to induce immune tolerance in these individuals, aiming to prevent rejection of the transplanted tissues.
• Patients with autoimmune diseases or severe allergies: This category encompasses individuals suffering from conditions where their immune system attacks its own tissues (autoimmune diseases) or exhibits hypersensitivity reactions (allergies). Aditxt's ADi products are being developed to offer therapeutic solutions by reprogramming the immune system to achieve tolerance.

Amro Albanna, Chief Executive Officer

Amro Albanna is a co-founder, Chairman, and Chief Executive Officer of Aditxt, a role he has held since the company's inception in 2017. He is a serial innovation entrepreneur who has founded eight startups to commercialize innovations across diverse industries including enterprise software, research incubation, GPS & wireless, nano sensors, consumer health, and biotech. Mr. Albanna has led multiple M&A and going-public transactions as a founder, co-founder, or senior executive. Notably, he co-founded Timely Technology Corporation, an e-commerce software company, which was later sold to a Nasdaq-listed company. He has experience in taking ventures public on various stock exchanges.

Thomas J. Farley, Chief Financial Officer

Thomas J. Farley serves as the Chief Financial Officer of Aditxt. Prior to joining Aditxt, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America ("BDCA"), a publicly listed business development company, from December 2015 to June 2020. From January 2011 to August 2015, he held the position of Senior Controller at Blackrock Capital Investment Corporation (NASDAQ: BKCC). Before these roles, he was a manager at Ernst & Young LLP.

Rowena Albanna, Chief Operating Officer

Rowena Albanna brings over 20 years of leadership experience spanning biotechnology, health innovation, and technology to her role as Chief Operating Officer. She previously managed operations for a commercialization platform focused on advancing innovative technologies and also founded and operated an e-commerce business.

Shahrokh Shabahang, MS, PhD, Co-founder, Chief Innovation Officer, Board Member

Shahrokh Shabahang is a co-founder, Chief Innovation Officer, and Board Member of Aditxt. He possesses over 20 years of experience in commercializing life science technologies, with a focus on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, Chief M&A Officer

Corinne Pankovcin serves as the Chief M&A Officer for Aditxt. Her background includes serving as Chief Financial Officer for several world-class organizations.

1. Significant Financial Strain and Going Concern Doubt: Aditxt faces severe financial challenges, with substantial net losses, accumulated deficits, and negative free cash flow. For instance, the company reported a net loss of $7.4 million in Q2 2025 and an accumulated deficit of $168 million by the end of 2024. Its revenue has also dramatically decreased, with Q2 2025 sales at just $1,004. The company has a low cash balance, a significant working capital deficit, and overdue vendor obligations, leading to substantial doubt about its ability to continue as a going concern beyond one year.
2. Shareholder Dilution and Stock Price Volatility: Aditxt's stock price has experienced extreme volatility and a catastrophic decline, with a drop of approximately 99.95% over 52 weeks as of November 2025. The company has resorted to reverse stock splits to maintain its Nasdaq listing. There is a significant risk of further dilution for existing shareholders due to the potential issuance of shares underlying existing options, warrants, convertible preferred stock, and agreements to sell additional shares through equity lines. Such sales could cause a further decline in the market price of the common stock.
3. Inherent Risks of Biotechnology Development and Commercialization: As a biotechnology company, Aditxt operates in a high-risk sector characterized by deep losses during research, development, and commercialization phases. The company faces challenges related to the lengthy and uncertain regulatory approval process for its products, the ability to secure strategic partnerships for development and commercialization, and the protection and enforcement of its intellectual property. Bringing new medical technologies to market is inherently difficult and contributes to operational hurdles.

Aditxt, Inc. (ADTX) targets several significant addressable markets with its immune mapping and reprogramming technologies.

AditxtScore (Immune Mapping and Monitoring)

The global addressable market for technologies related to immune mapping and monitoring, specifically the immune repertoire sequencing market, was valued at approximately USD 369.93 million in 2025. This market is projected to grow to approximately USD 837.20 million by 2033, demonstrating a compound annual growth rate (CAGR) of 10.78%.

Apoptotic DNA Immunotherapy (ADI)

Aditxt's Apoptotic DNA Immunotherapy (ADI) targets several large therapeutic markets globally:

• Organ Transplantation: The global organ transplantation market was valued at around USD 18.59 billion in 2023 and is projected to reach approximately USD 33.32 billion by 2032, growing at a CAGR of 6.70%.
• Skin Grafting: The global market for skin grafts was valued at approximately USD 1.44 billion in 2024 and is expected to reach USD 3.08 billion by 2032, with a CAGR of 9.97% from 2025 to 2032.
• Autoimmune Diseases: The global autoimmune diseases treatment market is estimated to be valued at approximately USD 160.0 billion in 2026 and is projected to grow to USD 250.3 billion by 2033, expanding at a CAGR of 6.6% during the forecast period.
• Allergies: The global allergy treatment market size was valued at approximately USD 23.05 billion in 2024 and is expected to reach USD 38.24 billion by 2032, growing at a CAGR of 6.53%.

Aditxt (ADTX) anticipates several key drivers for future revenue growth over the next two to three years, primarily stemming from the advancement of its therapeutic pipeline, expansion of its diagnostic platforms, strategic acquisitions, and entry into new markets.

1. Advancement and Commercialization of ADi™ Therapeutics: Aditxt expects future revenue growth from the advancement of its Apoptotic DNA Immunotherapy (ADi™) pipeline, particularly its lead product candidate, ADI-100. The company plans to move ADi™ therapeutics into clinical trials in the coming months, with intentions to seek FDA submission and approval for first-in-human trials by early 2026. These trials will target high-need conditions such as psoriasis, type 1 diabetes, and stiff person syndrome. The global autoimmune therapeutics market, which Aditxt is targeting, is estimated to exceed $160 billion by 2030, presenting a substantial market opportunity for successful product development and commercialization.
2. Broader Applications, Distribution, and Reimbursement Expansion for AditxtScore™: Aditxt aims to drive revenue growth by expanding the applications and market reach of its AditxtScore™ platform. While the demand for COVID-19 diagnostics is expected to decline, Aditxt plans to leverage its existing infrastructure to develop broader applications for the platform. The company is actively establishing new distribution channel partners across the U.S. and globally. Furthermore, Aditxt intends to expand reimbursement coverage for AditxtScore™ for COVID-19 from private and public payers, concurrently developing and commercializing tests for other indications.
3. Pearsanta's Planned IPO and Commercialization of Diagnostic Tests: Aditxt's precision diagnostics subsidiary, Pearsanta, is slated for an initial public offering (IPO) expected in 2026, subject to market conditions. Pearsanta is focused on commercializing its Mitomic® and Adductomics testing platforms for the early detection of cancer and other diseases. The subsidiary is currently completing clinical validation studies and expanding its operations through its CLIA/CAP-certified laboratory, which is anticipated to contribute to future revenue streams from these diagnostic offerings.
4. Expansion into Women's Health Market: Aditxt is strategically expanding into the women's health market through its proposed acquisition of Evofem, under an amended merger agreement. Evofem commercializes FDA-approved products such as PHEXXI®, a hormone-free contraceptive gel, and SOLOSEC®, a single-dose therapy for bacterial vaginosis. This expansion is expected to introduce new revenue streams and leverage Aditxt's portfolio within a new therapeutic area, with the transaction targeted to close in the second half of 2025.
5. Integration and Leverage of Ignite Proteomics Acquisition: In March 2026, Aditxt completed the acquisition of Ignite Proteomics from IMAC Holdings. While the immediate stock reaction was a decline, this acquisition boosts Aditxt's stockholders' equity and enhances its equity position. As Aditxt focuses on monitoring and modulating the immune system, the integration of Ignite Proteomics' capabilities is expected to expand Aditxt's offerings and potentially lead to new or enhanced revenue streams in the future.

Share Issuance

• Aditxt implemented multiple reverse stock splits to comply with Nasdaq's minimum bid price requirement, including a 1-for-250 split effective March 17, 2025, a 1-for-113 split effective November 3, 2025, and a 1-for-8 split effective March 9, 2026.
• The company has conducted Post-IPO funding rounds, with its largest occurring in September 2023.
• Aditxt issued 36,000 shares of Series A-2 Convertible Preferred Stock, valued at $36 million, to acquire Ignite Proteomics in March 2026.

Inbound Investments

• Aditxt secured $256,250 through the private sale of senior notes at a 10% interest rate, maturing in May 2025, and issued $212,500 in similar notes maturing in September 2025.
• The company's CEO provided an unsecured loan of $233,000 in May 2025, with an annual interest rate of 7.5%.
• Aditxt temporarily suspended equity financing activities to focus on debt financing as its primary strategy for funding acquisitions.

Outbound Investments

• As part of a merger agreement with Evofem Biosciences, Aditxt made equity investments totaling $1.72 million by October 2024, with additional planned investments of $2.28 million and a further $1.5 million by April 2025.
• Aditxt acquired Ignite Proteomics in March 2026 for $36 million, paid in Series A-2 Convertible Preferred Stock.
• The company is pursuing the proposed acquisitions of Evofem Biosciences and Appili Therapeutics, with an estimated $17 million in additional cash required to complete the Evofem acquisition.